Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis
NCT06590545
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
8
Enrollment
OTHER
Sponsor class
Conditions
ANCA-IgG-positive ANCA Associated Vasculitis
Interventions
DRUG:
KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy
Sponsor
David Simon
Collaborators
[object Object]